Research programme: pain therapeutics - DURECT Corporation
Alternative Names: DUROS hydromorphoneLatest Information Update: 04 Nov 2017
At a glance
- Originator DURECT Corporation
- Class Morphinans
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
- Discontinued Cancer pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
- 10 Jul 2007 Discontinued - Preclinical for Cancer pain in USA (Intrathecal)
- 10 Jul 2007 Preclinical trials in Pain in USA (unspecified route)